🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

82 results for “Chen” Clear

  1. A Phase II Multicenter, Open-Label Study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Pediatric Patients with Duchenne Muscular Dystrophy (SHIELD DMD)

    Hoffmann-La Roche

    Duchenne Muscular Dystrophy (DMD)

    phase 2 other active

    1 trial

  2. AVI-4658 (Eteplirsen)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule completed

    1 trial

  3. AVI-4658 (Eteplirsen)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  4. AVI-4658 (PMO)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  5. AVI-4658 for Injection

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  6. Allogeneic Cardiosphere-Derived Cells (CAP-1002)

    CAPRICOR THERAPEUTICS, INC.

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    2 trials

  7. Amondys 45

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  8. Ataluren

    PTC THERAPEUTICS, INC.

    Nonsene Mutation Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  9. BMN 044 IV 6 mg/kg

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  10. BMN 351

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  11. BMN 351

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  12. Budenofalk 4 mg Zäpfchen, placebo to test

    Dr. Falk Pharma GmbH

    Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma

    phase 2 small molecule active

    1 trial

  13. DA-302168S

    Chendu DIAO Pharmaceutical Group CO., LTD.

    Overweight and Obesity

    phase 2 small molecule active

    1 trial

  14. DS-5141b

    Daiichi Sankyo

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  15. DT-DEC01

    Wuhan Createrna Science and Technology Co., Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  16. DYNE-251

    Dyne Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  17. Delandistrogene moxeparvovec-rokl

    Hoffmann-La Roche

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  18. Deramiocel (CAP-1002)

    CAPRICOR THERAPEUTICS, INC.

    Duchenne Muscular Dystrophy

    phase 2 mab active

    1 trial

  19. ENTR-601-44

    Entrada Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  20. ENTR-601-44, SODIUM CHLORIDE

    Entrada Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  21. ENTR-601-45

    Entrada Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  22. Eteplirsen

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    2 trials

  23. Exon 51 specific phosphorothioate oligonucleotide

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  24. Exon 51 specific phosphorothioate oligonucleotide

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources